A lean-looking Elon Musk revealed Wednesday that he uses Mounjaro — after previously expressing support for similar weight-loss drugs as a means to curb America’s obesity epidemic.
The billionaire Tesla, SpaceX and X boss made the admission in a social media post, where he included an image of himself donning a Santa Claus suit and flowing white beard.
Musk dubbed himself “Ozempic Santa” in the X post, noting it’s “Like Cocaine Bear, but Santa and Ozempic!”
“Technically, Mounjaro, but that doesn’t have the same ring to it,” he clarified.
Mounjaro, like Ozempic, is a GLP-1 inhibitor – a class of drugs developed to help people with diabetes regulate their blood glucose and insulin levels.
However, Americans have increasingly been using GLP-1 inhibitors to successfully shed pounds.
Musk, 53, noted that he prefers Mounjaro to Ozempic because taking “high doses” of the latter drug made him “fart & burp like Barney from the Simpson’s.”
“Mounjaro seems to have fewer side effects and be more effective,” the incoming head of President-elect Donald Trump’s Department of Governmental Efficiency said.
Musk has long argued for widespread use of GLP-1 inhibitors to combat obesity – a position that clashes with Health and Human Services Secretary-designate Robert F. Kennedy Jr.’s stance on the medication.
Kennedy, 70, has contended that getting Americans to eat healthier would be a more cost-effective way of handling the obesity crisis.
Musk’s support for GLP-1 inhibitors has earned him praise from the liberal hosts of “The View,” one of whom, Whoopi Goldberg, has also admitted taking Mounjaro.
“Elon’s right on this!” Goldberg declared during a discussion earlier this month on the division between the incoming DOGE chief and HHS secretary.
The 69-year-old comedian later showed off her own trim figure after revealing to the audience that she weighed close to 300 pounds two years ago before she started taking Mounjaro.
Musk, who has publicly proclaimed that he doesn’t like working out, previously admitted to using Wegovy, another GLP-1 inhibitor, in 2022.
